Vagal Nerve-Based Disorders
AssigneeAllergan, Inc.
InventorsAndrew M. BLUMENFELD, Mitchell F. Brin
Life of this patent
Estimating the term…
Abstract
The present specification discloses TEMs, compositions comprising such TEMs, compositions comprising such TEMs and Clostridial toxins, methods of treating a vagal nerve-based disorder in an individual using such compositions, use of such TEMs in manufacturing a medicament for treating a vagal nerve-based disorder, use of such TEMs and Clostridial toxins in manufacturing a medicament for treating a vagal nerve-based disorder, use of such TEMs in treating a vagal nerve-based disorder, and use of such TEMs and Clostridial toxins in treating a vagal nerve-based disorder.
Claims13
A method of treating a vagal nerve-based disorder in an individual, the method comprising the step of administering to a nerve from the vagal nerve complex of the individual in need thereof a therapeutically effective amount of a composition including a TEM comprising a targeting domain, a Clostridial toxin translocation domain and a Clostridial toxin enzymatic domain, wherein the targeting domain is a sensory neuron targeting domain, a sympathetic neuron targeting domain, or a parasympathetic neuron targeting domain, and wherein administration of the composition reduces or inhibits activity from the nerve from the vagal nerve complex, thereby reducing a symptom of the vagal nerve-based disorder in the individual.
A method of treating a vagal nerve-based disorder in an individual, the method comprising the step of administering to a nerve from the vagal nerve complex of the individual in need thereof a therapeutically effective amount of a composition including a TEM comprising a targeting domain, a Clostridial toxin translocation domain, a Clostridial toxin enzymatic domain, and an exogenous protease cleavage site, wherein the targeting domain is a sensory neuron targeting domain, a sympathetic neuron targeting domain, or a parasympathetic neuron targeting domain, and wherein administration of the composition reduces or inhibits activity from the nerve from the vagal nerve complex, thereby reducing a symptom of the vagal nerve-based disorder in the individual.
A use of a TEM in the manufacturing a medicament for treating a vagal nerve-based disorder in an individual in need thereof, wherein the TEM comprising a targeting domain, a Clostridial toxin translocation domain and a Clostridial toxin enzymatic domain, wherein the targeting domain is a sensory neuron targeting domain, a sympathetic neuron targeting domain, or a parasympathetic neuron targeting domain.
A use of a TEM in the manufacturing a medicament for treating a vagal nerve-based disorder in an individual in need thereof, wherein the TEM comprising a targeting domain, a Clostridial toxin translocation domain, a Clostridial toxin enzymatic domain, and an exogenous protease cleavage site, wherein the targeting domain is a sensory neuron targeting domain, a sympathetic neuron targeting domain, or a parasympathetic neuron targeting domain.
Dependencies are inferred from the claim text.